key: cord-0819543-au6fxb7f
authors: Naeini, Mehri Bemani; Sahebi, Mahdieh; Nikbakht, Fateme; Jamshidi, Zahra; Ahmadimanesh, Mahnaz; Hashemi, Maryam; Ramezani, Javad; Miri, Hamid Heidarian; Yazdian-Robati, Rezvan
title: A Meta-Meta-Analysis: evaluation of Meta-Analyses Published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19
date: 2021-01-23
journal: Obes Med
DOI: 10.1016/j.obmed.2021.100323
sha: c697aa10eb7139ef4d3b9f7822c885d720671992
doc_id: 819543
cord_uid: au6fxb7f

On January 2020, WHO confirmed the epidemic outbreak of SARS-CoV-2 as a Health Emergency of International Concern. The aim of this meta-meta-analysis is quantifying meta-analytic findings on the association of cardiovascular disease (CVD) comorbidities and COVID-19 severity. Findings suggest that chances of getting severe COVID-19 disease in patients with CVD is greater than those without CVD. Also, prevalence of CVD in patents with COVID-19 is 0.08 (95% CI =0.07-0.08). The OR as 3.44 indicates that the odds of getting severe COVID-19 is more than 3 times higher in those with CVD. Also, prevalence of hypertension in patient with COVID-19 is 0.27 (95%CI= 0.27-0.28) and the OR as 2.68 indicates that the odds of getting severe COVID-19 in cases with high blood pressure is more than 2.5 times higher than those without hypertension. It is rational to suppose that persons with coronary artery disease are prone to severe viral infection thereby, guideline-directed diagnosis and medical therapy is vital in CVD patients.

Coronavirus disease-2019 (COVID-19) is a global health emergency caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has already developed into a pandemic spreading rapidly around the globe (Organization, 2020) . SARS-CoV-2 appears to infect the host cells through angiotensin converting enzyme 2 (ACE2) receptors, which are widely expressed not only in epithelial cells of airways, but also in heart and blood vessels. Thus, ACE2-related biological pathways may play a role in heart damage associated with COVID-19. While the clinical presentations of SARS-CoV-2 infection are known by the resulting respiratory symptoms, increasingly studies reported that some patients have developed cardiovascular disorders . Importantly, based on different reports in several countries, people with underlying CVDs present with substantially greater risk of death from the SARS-COV-2, So, extra care against infection are being urged . Another phenomenon that play a key role in COVID-19 is the imbalanced cytokine storm response of type 1/ type 2 T helper cells, resulting in fever and multiple organ dysfunction and cardiac injury .Immune system activation may cause plaque vulnerability, contributing to the progress of acute coronary events. The common laboratory abnormalities show that SARS-CoV-2 infection may be related to cellular immunodeficiency, activation of coagulation cascade, liver and kidney damage and myocardial injury (Cui et al., 2020) . Due to the poor prognosis, patients with existing cardiovascular disease (CVD) are prone to the adverse effects of COVID-19 infection. According to National Health Commission of China (NHC), among the confirmed cases of the illness, some patients visited a doctor's office for CV symptoms, palpitations and chest discomfort and tightness rather than respiratory symptoms and signs (high fever and cough), although were later identified and diagnosed with . Prevalence of myocardial damage and its intensity is high in severe ill patients with COVID-19, leading to a higher possibility of in-hospital mortality (Cui et al., 2020) . The patients with concomitant heart disease are hypothetically at the greatest risk of contracting the COVID-19 infection. The acute inflammatory response induced by the infection may aggravate cardiac function. We have performed this analysis, using data based searching to identify the proportion of the disease severity and comorbidities such as cardiovascular disorders.

J o u r n a l P r e -p r o o f

COVID-19 appears to promote the development of CV disorders, such as acute coronary syndrome (ACS), myocardial injury, arrhythmias, and venous thromboembolism. Systemic inflammation related to COVID-19 has been suggested to accelerate the development of subclinical disorders or even lead to de novo CV damage. ACE2, a key part of the reninangiotensin-aldosterone system (RAAS), which is thought to facilitate cellular coronaviruses entry (Ziegler et al., 2020) , leading to myocardial damage, endothelial and microvascular dysfunction, plaque vulnerability, and MI (Guzik et al., 2020) . The possible mechanisms of myocardial damage caused by COVID-19 infection are as follows: (1) direct injury: viral infection can directly cause damage to myocardial cells (Knowlton, 2020) ;(2) immune injury:

The resulting over-activation of the immune system produces an extreme immune response and releases a large amount of cytokines (Java et al., 2020; Wiersinga et al., 2020) . In addition, the promotion of immune system dysregulation occurs during disturbtion of blood pressure, suggesting another mechanism connecting arterial hypertension and COVID-19. CD8+ T cell dysfunction observed in hypertensive patients (Youn et al., 2013) , results in insufficient combating viral infections and might be associated with an excess cytokine production, augmenting the risk of complications. Effective control of hypertension by medication use can moderately reverse the dysregulation of the immune response in high blood pressure. Arterial hypertension can be considered as the main predictor of disease severity or a causal factor of late deterioration in the disease course, which is characterized by acute respiratory distress syndrome (ARDS) and systemic inflammatory response and/or multiple organ failure syndromes . Generally, ACE2 overexpression in failing hearts, suggests an acceptable explanation for higher infection and more mortality in patients with heart failure . Also, cellular entry of coronaviruses through ACE2 has associations in vascular instability in infected patients who have pre-existing hypertensive disorders (Guzik et al., 2020) .

J o u r n a l P r e -p r o o f A total of 408 articles were retrieved using the electronic databases: PubMed, SCOPUS and Science direct and the search terms: 2019 novel coronavirus and COVID-19" and "Cardiovascular Diseases" and "comorbidities, meta-analysis, clinical characteristics and associated MeSH terms. The meta-meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement (PRISMA). A total of 49 articles were finally included in this analysis. 

The meta-analysis of single arm studies was performed by statistical software Stata version 14.0

and Open Meta-analyst. We unify all units of variables, and categorized variables are expressed as percentages, and continuous variables are expressed as Means ± SDs. The combined prevalence and 95% CI were determined by a random-effects model. Meta-analysis of Odds

Ratio was performed on the natural logarithm scale and then returned to its original scale.

Studies were pooled with fixed-effects meta-analytic models in order to combine odds ratios (OR) and prevalences and their 95% confidence intervals (CIs). Heterogeneity of effect size across trials was established based on I 2 more than 0.50. However, as effect sizes were extracted from meta-analysis papers, there was no sufficient information to deal with heterogeneity through subgroup analysis or meta-regression. So in case of high I 2 , the results should be interpreted with caution. Publication bias was assessed using funnel plots, as well as, Egger's linear regression test and Begg's rank correlation test. When publication bias was identified, a nonparametric trim and fill method was performed to adjust the publication bias.

A comprehensive literature search was performed using PubMed, Scopus, and Science Direct from April until December, 2020. This meta-meta-analysis, included 45 meta-analyses, containing patients with novel coronavirus disease (Tables 1-4 Odd ratio of CVD:

Figure4: Forest plot for Odds Ratio for association between cardiovascular disease and severe/nonsevere patient of COVID-19. Each square (■) and its horizontal line, respectively, represent the OR and its 95% CI for each individual study (the size of the grey square corresponds to the weight of that study in the meta-analysis); the diamond and its horizontal diagonal (◊) show the combined overall OR and its 95% CI, respectively. The OR as 3.44 indicates that the odds of getting severe COVID-19 from cardiovascular disease is 3.44 times J o u r n a l P r e -p r o o f higher in those without cardiovascular disease. (OR=3.44 & 95%CI=3.18-3.72, P=0.000, I =30.14%).

The funnel plot of OR for CVD is approximately symmetric that in accord to results of Egger's (P=0.269) and Begg's (P=0.628) tests faded the possibility of the potential publication bias. However, to further assess the effect of missing studies on the summary effect, the trim and fill approach was applied and showed that after filling the missing studies the summary effect didn't change significantly. and its horizontal line, respectively, represent the prevalence and its 95% CI for each individual study (the size of the grey square corresponds to the weight of that study in the meta-analysis); the diamond and its horizontal diagonal (◊) show the combined overall prevalence and its 95% CI, respectively. Prevalence of hypertension in patent with COVID-19 is 0.27 (95%CI =0.27-0.28, = 0.000, I =98.5%) Figure 7 : The funnel plot of prevalence for hypertension is approximately symmetric that in accord to results of Egger's (P=0.000) and Begg's (P=0.009) tests faded the possibility of the potential publication bias. However, to further assess the effect of missing studies on the summary effect, the trim and fill approach was applied and showed that after filling the missing J o u r n a l P r e -p r o o f studies the estimated prevalence of CVD didn't significantly change but estimated prevalence of hypertension increased from 0.27 (0.27 -0.28) to 0.323 (0.318 -0.328).

J o u r n a l P r e -p r o o f However, to further assess the effect of missing studies on the summary effect, the trim and fill approach was applied and showed that after filling the missing studies the summary effect didn't change significantly.

To assess the impact of individual studies on the summary effect the influential anal analysis was performed and the results indicated that none of the summary effects was sensitive to individual studies. In other words, after eliminating of each study, the change in the summary effect was not statistically significant.

J o u r n a l P r e -p r o o f

As described in analysis of COVID-19 patients, hypertension and severe myocardial injury contribute to disease severity and mortality of these patients (Nishiura et al., 2020) . People with basic CVD are more likely to be infected with the virus, and the virus infection can also lead to the deterioration of basic heart disease. In COVID-19 cases, it is important to recognize the clinical characteristics of patients in order to aid in early and rapid detection of infected persons, as well as to reduce patient mortality. Since many antiviral drugs can cause cardiac insufficiency, arrhythmia or other CV disorders, therefore, during treatment of the disease, especially with antiviral therapy, the risk of cardiac toxicity needs be closely monitored (Sakabe et al., 2013) .

More attention should be paid to patients with extremely increased cardiac cTnI levels-major plasma biomarker for the identification of myocardial infarction and cell necrosis in an ACS-and new cases of arrhythmias (Park et al., 2017) . The common laboratory abnormalities demonstrate that 2019-nCoV infection may be associated with cell-mediated immune deficiency, coagulation activation, myocardial injury, and liver and kidney damage. These abnormal laboratory results, are similar to those previously reported in patients with MERS-CoV and SARS-CoV infection (Meo et al., 2020) . Due to the poor prognosis, patients with CVD are special cases of COVID- . Therefore, an extreme inflammatory response, along with pre-existing CVD may cause to development of cardiac disease in patients with COVID-19 infection.In other words, COVID-19 patients with CV basic diseases, are suggested to give main concern to treatment, and more attention against the recurrence or augmentation of the original basic pathological disorders Channappanavar and Perlman, 2017) . Furthermore, results showed that hypertension was related to the severity of COVID-19 infection and in patients with both hypertension and COVID-19, treatment is dependent on their conditions. Seemingly, the intensive care unit (ICU) patients had a greater number of comorbid conditions than those with no ICU admissions. This proposes that comorbidity may be potential risk factors for poor outcome (15). Consequently, a better understanding of the impacts of CVD will be necessary for the management of COVID-19

patients. Some experts suggest that, during the outbreak, people with previous CVD should firmly consume optimized drug regimens in accordance with health center guidance to provide further protection (Ferrario et al., 2005) .

In conclusion, the present meta-analysis focused on the association between CVD risk and hypertension and severity of COVID-19. Our meta-analysis revealed that CVD and hypertension could be considered as potential risk factors for severity of the disease. Considering the connection exist between chronic CVD and COVID-19, will aid the health sector guide to distinguish high risk people and deliberate the risk factors of deterioration. Diabetes, respiratory system disease, and CVD were known as hypothetically key risk factors that should be encompassed in recommended future vaccination schedule. Collectively, underlying basic diseases such as hypertension and CVD are risk factors for disease progression and development.

This is consistent with our analytical results obtained in this paper. 

No funding was received

The authors declare that they have no conflict of interest.

This article does not contain any studies with human participants or animals performed by any of the authors.

Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis

Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: a meta-analysis. Current Problems in Cardiology100617

Prevalence of Comorbidities and Their Association With Mortality in Patients With COVID-19: A Systematic Review and Meta-analysis. Diabetes, obesity & metabolism

Prevalence of comorbidities in COVID-19 patients: A systematic review and meta-analysis. Archives of Bone and Joint Surgery

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Factors associated with disease severity and mortality among patients with COVID-19: A systematic review and meta-analysis

A 55-day-old female infant infected with 2019 novel coronavirus disease: presenting with pneumonia, liver injury, and heart damage

Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis

Features of severe COVID-19: A systematic review and meta-analysis

Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Archives of academic emergency medicine

Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and metaanalysis

COVID-19 and comorbidities: a systematic review and meta-analysis

COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet

Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis

The complement system in COVID-19: friend and foe? JCI insight. 5 (15)

Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis

The Prevalence of Underlying Diseases and Comorbidities in COVID-19 Patients; an Updated Systematic Review and Meta-analysis. Archives of academic emergency medicine

Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus

Epidemiological and Clinical Characteristics of Cases During the Early Phase of COVID-19 Pandemic: A Systematic Review and Meta-Analysis

Coronavirus disease 2019 (COVID-19) and cardiovascular risk: A meta-analysis

Clinical features of COVID-19 and factors associated with severe clinical course: a systematic review and meta-analysis

Cardiovascular complications in COVID-19: A systematic review and meta-analysis

Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia

Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis

Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. Expert review of anticancer

The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis

The epidemiological burden of and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: Evidence from a systematic review and meta-analysis

A Meta-Analysis of 67 Studies with Presenting Symptoms and Laboratory Tests of COVID-19 Patients

Impact of cardiovascular and metabolic diseases on the severity of COVID-19: a systematic review and meta-analysis

Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV

Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool

Predictors of COVID-19 severity: a systematic review and meta-analysis

Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events

COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review and Meta-analysis

The extent of transmission of novel coronavirus in Wuhan

Naming the coronavirus disease (COVID-19) and the virus that causes it

Association of diabetes and hypertension with disease severity in covid-19 patients: A systematic literature review and exploratory metaanalysis. Diabetes research and clinical practice

Age-adjusted risk factors associated with mortality and mechanical ventilation utilization amongst COVID-19 hospitalizations-a systematic review and meta-analysis

Comorbidities and clinical severity of COVID-19: systematic review and meta-analysis. Rev. habanera cienc

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel medicine and infectious disease101623

Impact of cardiovascular risk profile on COVID-19 outcome. A meta-analysis

Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C

Global impact of coronavirus disease 2019 infection requiring admission to the ICU: a systematic review and meta-analysis

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis

Multi-organ dysfunction in patients with COVID-19: a systematic review and meta-analysis

Characterisation of clinical, laboratory and imaging factors related to mild vs. severe covid-19 infection: a systematic review and meta-analysis

Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Immunosenescent CD8+ T cells and CXC chemokine receptor type 3 chemokines are increased in human hypertension

Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study

COVID-19 and the cardiovascular system

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and metaanalysis

SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues